| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/05/2012 | US20120004315 Selective Estrogen Receptor Modulator |
| 01/05/2012 | US20120004312 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 01/05/2012 | US20120004303 Method of dispensing a teething gel with a metered dose applicator |
| 01/05/2012 | US20120004290 Treating chronic fatigue syndrome and prolonged qt interval |
| 01/05/2012 | US20120004248 Methods of using a methylxanthine compound |
| 01/05/2012 | US20120004233 Tricyclic compounds as antagonists of prostaglandin d2 receptors |
| 01/05/2012 | US20120004232 2-amino-bicyclo(3.1.0) hexane-2, 6-dicarboxylic ester derivative |
| 01/05/2012 | US20120004216 Modulators of atp-binding cassette transporters |
| 01/05/2012 | US20120004215 N-oxides of diazabicyclononyl pyrimidine derivatives and their medical use |
| 01/05/2012 | US20120004209 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds |
| 01/05/2012 | US20120004203 Triazolo and tetrazolo pyrimidine derivatives as hne inhibitors for treating copd |
| 01/05/2012 | US20120004201 Phosphodiestarase inhibitors |
| 01/05/2012 | US20120004185 Polypeptide structural motifs associated with cell signaling activity |
| 01/05/2012 | US20120004157 Hydroxyproline compositions and uses thereof |
| 01/05/2012 | US20120003313 Dpp iv inhibitor formulations |
| 01/05/2012 | US20120003295 Lipid a and other carbohydrate ligand analogs |
| 01/05/2012 | US20120003243 Yeast ectopically expressing abnormally processed proteins and uses therefor |
| 01/05/2012 | US20120003229 Modulators of cytokine mediated signalling pathways and integrin alphavbeta3 receptor antagonists for combination therapy |
| 01/05/2012 | US20120003217 Herceptin® aduvant therapy |
| 01/05/2012 | US20120003214 Binding Moieties Based On Shark IgNAR Domains |
| 01/05/2012 | US20120003189 Materials and Methods to Enhance Hematopoietic Stem Cells Engraftment Procedures |
| 01/05/2012 | US20120003185 Bone-like prosthetic implants |
| 01/05/2012 | US20120003153 Novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use |
| 01/05/2012 | CA2804225A1 Heterocyclic compound and p27kip1 degradation inhibitor |
| 01/05/2012 | CA2803842A1 Novel nicotinamide derivative or salt thereof |
| 01/05/2012 | CA2803010A1 Dissolvable fibrous web structure article comprising active agents |
| 01/04/2012 | EP2402314A1 (Aza)indole derivative and use thereof for medical purposes |
| 01/04/2012 | EP2402310A1 CCR9 inhibitors and methods of use thereof |
| 01/04/2012 | EP2402309A1 CCR9 inhibitors and methods of use thereof |
| 01/04/2012 | EP2402038A1 Telomerase reverse transcriptase for protection against ageing |
| 01/04/2012 | EP2402034A1 A method for screening for a substance having an action of proliferating natural killer cells |
| 01/04/2012 | EP2402033A1 Cell adhesion inhibitor and use thereof |
| 01/04/2012 | EP2402010A1 Solid drug for oral use |
| 01/04/2012 | EP2402009A1 Inhibitors of serine protease, particularly hepatitis c virus NS3-NS4A protease, incorporating a fused ring system |
| 01/04/2012 | EP2402007A1 Coenzyme q10-containing composition for oral ingestion |
| 01/04/2012 | EP2401268A1 Oxyindole derivatives with motilin receptor agonistic activity |
| 01/04/2012 | EP2400989A1 Oligomer-amino acid conjugates |
| 01/04/2012 | EP1441720B1 Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system |
| 01/04/2012 | EP1339663B1 Naphthalene derivatives |
| 01/04/2012 | CN102307871A Isoindolinone and related analogs as sirtuin modulators |
| 01/04/2012 | CN102307861A Phenylimidazole compounds |
| 01/04/2012 | CN102307847A Indanyl compounds |
| 01/04/2012 | CN102307598A Pharmaceutical compositions comprising TGF-beta1 inhibitor peptides |
| 01/04/2012 | CN102304179A GLP-1 and exendin related invention |
| 01/04/2012 | CN102302736A Traditional Chinese medicine for treating lipoma disease |
| 01/04/2012 | CN102302618A Summer-heat relieving agent |
| 01/04/2012 | CN102302507A Medicinal composition for directional controlled release of trace elements and preparation method and application |
| 01/04/2012 | CN102302494A Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| 01/04/2012 | CN102302446A Recombinant human growth hormone injection capable of being directly used |
| 01/04/2012 | CN102058625B High-efficient anti-stress agent for aquaculture |
| 01/04/2012 | CN102008686B Chinese medicament for treating sarcoidosis |
| 01/04/2012 | CN101838266B Citric acid tropisetron raw material medicine and preparation technology of raw material medicine and injection liquid |
| 01/04/2012 | CN101810693B Chinese medicament for treating postpartum cold sweat and preparation method thereof |
| 01/03/2012 | US8088924 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor |
| 01/03/2012 | US8088921 Method for producing 3-amidinophenylalanine derivatives |
| 01/03/2012 | US8088828 Treating benign prostate hyperplasia with SARMS |
| 01/03/2012 | US8088825 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 01/03/2012 | US8088813 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| 01/03/2012 | US8088802 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation |
| 01/03/2012 | US8088762 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 01/03/2012 | US8088726 Process for producing sustained-release composition |
| 01/03/2012 | US8088407 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| 01/03/2012 | US8088383 Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies |
| 01/03/2012 | CA2632556C Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 01/03/2012 | CA2615173C Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
| 01/03/2012 | CA2514407C Thienopyrimidine compounds and use thereof |
| 01/03/2012 | CA2512434C Sustained-release pharmaceutical composition comprising carrageenan for lung administration |
| 01/03/2012 | CA2508932C Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same |
| 01/03/2012 | CA2496902C Medicament for activating the phagocytic capacity of macrophages |
| 01/03/2012 | CA2491612C 4-'7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents |
| 01/03/2012 | CA2490200C 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
| 01/03/2012 | CA2489128C 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections |
| 01/03/2012 | CA2488565C Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom |
| 01/03/2012 | CA2486712C Method of treating diabetes |
| 01/03/2012 | CA2480423C Truncated 24 kda basic fibroblast growth factor |
| 01/03/2012 | CA2480356C Benzamide derivatives useful as histone deacetylase inhibitors |
| 01/03/2012 | CA2468910C Use of 4-oxobutanoic acid derivatives in the treatment of inflammation |
| 01/03/2012 | CA2466054C Apo-2 ligand/trail formulations |
| 01/03/2012 | CA2465117C Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
| 01/03/2012 | CA2464309C Combinations comprising a selective cyclooxygenase-2 inhibitor |
| 01/03/2012 | CA2457636C Antigen binding domains |
| 01/03/2012 | CA2455972C N6-benzyl and phenyl substituted adenines and their use as cosmetics, pharmaceutical preparations and plant growth regulators |
| 01/03/2012 | CA2452151C Use of cyclopamine, an inducer of the differentiation and apoptosis of the basal cell carcinoma (bcc) cells, in the treatment of bcc's and other tumors that use the hedgehog/smoothened pathway for proliferation of apoptosis |
| 01/03/2012 | CA2446254C New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits |
| 01/03/2012 | CA2445835C 6h-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 01/03/2012 | CA2436049C A serpin in bifidobacteria |
| 01/03/2012 | CA2425558C Lactam compound |
| 01/03/2012 | CA2423220C Modified prodrug forms of ap/amp |
| 01/03/2012 | CA2420618C Percarboxylated polysaccharides, and a process for their preparation |
| 01/03/2012 | CA2397661C 2,4-disubstituted thiazolyl derivatives |
| 01/03/2012 | CA2397018C Compounds exhibiting thrombopoietin receptor agonism |
| 01/03/2012 | CA2388180C Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 01/03/2012 | CA2362507C Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant |
| 01/03/2012 | CA2347025C Zinc finger binding domains for gnn |
| 01/03/2012 | CA2224468C P53 protein variants and therapeutical uses thereof |
| 01/03/2012 | CA2217539C Urinary bladder submucosa derived tissue graft |
| 12/29/2011 | WO2011162419A1 Tumor growth controlling method targeting galactosylceramide expression factor-1 |
| 12/29/2011 | WO2011162409A1 Compounds having trpv1 antagonistic activity and uses thereof |
| 12/29/2011 | WO2011162300A1 Crystal of fused pyridine compound salt |
| 12/29/2011 | WO2011162274A1 Isoquinoline derivative |